Cardiovascular Revascularization Medicine心血管血运重建医学
Cardiovascular Revascularization Medicine(英文缩写 CARDIOVASC REVASCULA),ISSN 1553-8389,eISSN 1878-0938,中文译名:心血管血运重建医学 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 未收录 | N/A |
| 2022 | 1.700 | N/A |
| 2023 | 1.600 | Q3 |
| 2024 | 1.900 | Q3 |
| 2025 | 2.300 | Q3 |
Cardiovascular Revascularization Medicine 最新收录文献
-
2. Intravascular ultrasound (IVUS)-guided angioplasty for femoropopliteal (FP) peripheral artery disease: A Meta-analysis of its mid-term efficacy.
PMID:日期:2026-09-07Intravascular ultrasound (IVUS)-guided femoropopliteal (FP) angioplasty has emerged as a promising imaging-guided strategy in clinical practice. However, current evidence remains heterogeneous, and recently, two randomized controlled trials (RCTs) have provided additional insights into its efficacy. This meta-analysis aims to reevaluate the efficacy of IVUS-guided angioplasty for FP lesions and to better clarify its clinical impact. Four databases were systematically searched for studies comparing IVUS-guided angioplasty to angiography-only in FP lesions. Study quality was assessed using the Cochrane Risk of Bias Tool and Newcastle-Ottawa Scale. Meta-analysis was performed using an inverse-variance random-effects model using Rstudio version 2024.09.01. Six high quality studies were included (n = 1544 patients). The risk for primary patency and freedom of clinically driven-target lesion revascularization(cd-TLR) at 1 year was significantly higher in the IVUS-guided group compared to the angiography group (RR 1.27 (95%CI 1.13-1.42, I = 58.6%) and RR 1.10 (95%CI 1.01-1.20, I = 56.8%), respectively), but no significant difference was observed in freedom of amputation and mortality (RR 1.00 (95%CI 0.98-1.01, I2 = 0%) and RR 1.06 (95%CI 0.67-1.70, I2 = 0%), respectively). IVUS-guided FP angioplasty improves primary patency and reduced cd-TLR rates. Further studies with longer follow-up duration should be the research focus in order to understand the long-term efficacy.
-
3. Outcomes of surgical aortic valve replacement with coronary artery bypass grafting versus transcatheter aortic valve replacement with percutaneous coronary intervention.
PMID:日期:2026-09-03Aortic stenosis (AS) often coexists with coronary artery disease (CAD). Although transcatheter aortic valve replacement (TAVR) with percutaneous coronary intervention (PCI) is frequently performed, comparative data with surgical aortic valve replacement (SAVR) with coronary artery bypass grafting (CABG) remain limited. This study compared outcomes of TAVR plus PCI versus SAVR plus CABG in patients with severe AS and CAD. Data were obtained from the TriNetX Research Network, a large real-world retrospective database. Patients undergoing TAVR plus PCI or SAVR plus CABG between January 2015 to December 2022 were identified. After propensity score matching, 2483 patients were included in each group. Thirty-day outcomes included all-cause mortality, stroke, and permanent pacemaker (PPM) implantation. In addition, all-cause mortality at 1 and 3 years was determined. At 30 days, SAVR plus CABG was associated with higher all-cause mortality (4.2% vs 2.7%; p = 0.005) and higher incidence of stroke (5.5% vs 3.8%, p = 0.003) compared to TAVR plus PCI; however, PPM was lower in SAVR plus CABG (5.2% vs. 8.4%; p < 0.001). At 1-year, all-cause mortality was similar between SAVR plus CABG and TAVR plus PCI (10.4% vs. 11.1% [p = 0.70], respectively). At 3 years, SAVR plus CABG demonstrated lower all-cause mortality compared with TAVR plus PCI (18.7% vs 26.2%; p < 0.001). In patients with severe AS and CAD, SAVR with CABG is associated with higher short term all-cause mortality and stroke with lower PPM implantation compared to TAVR with PCI. Despite worse early outcomes, SAVR with CABG demonstrated superior long-term survival at 3 years.
-
6. The current and future in transcatheter treatment of aortic stenosis: from the 'Beyond the Guidelines' session at Cardiovascular Research Technologies 2026.
PMID:日期:2026-09-01The introduction of transcatheter aortic valve replacement (TAVR) over two decades ago has fundamentally reshaped the management and treatment landscape for the treatment of severe aortic stenosis by introducing a less invasive approach compared to a surgical aortic valve replacement (SAVR). The field continues to rapidly evolve as clinical studies expand the indications for TAVR across all surgical risk strata. However, it is unclear whether TAVR can be safely applied to patients with complex aortic valve and root pathologies as well as match the long-term durability demonstrated by SAVR. Thus, optimizing patient selection to maximize net clinical benefit, by defining the indications and limitations of TAVR, continue to be areas of active research and discourse. To this end, the annual 'Beyond the Guidelines' session at the 2026 Cardiovascular Research Technologies (CRT) convened an expert panel to highlight the current state of evidence, summarize the accumulated evidence in current domains of clinical equipoise where investigative efforts are focused, and identify key areas of clinical unmet need. This article summarizes the expert panel discussions of current evidence supporting the latest societal guidelines on management of severe aortic stenosis, the accumulation of investigative evidence in established clinical domains of equipoise including TAVR for aortic stenosis in asymptomatic patients; those with bicuspid aortic valves, treatment of transcatheter aortic valve failure, and expert opinions on emerging areas of unmet need where future investigative efforts may need to be focused.
-
7. Long-term causes of death in patients who underwent mitral transcatheter edge-to-edge repair.
PMID:日期:2026-09-01Transcatheter mitral edge-to-edge repair (M-TEER) has transformed the management of patients with severe mitral regurgitation (MR) at high or prohibitive surgical risk. However, data on long-term survival and causes of death after M-TEER remain limited. This single-center registry included consecutive patients undergoing M-TEER with the MitraClip device for severe MR between February 2016 and June 2020. The primary objective was long-term mortality trends and causes of death. Over a median follow-up of 3.3 years (IQR 1.3-5.1; maximum 8.5 years), 130 of 218 patients (59.6%) died, with 55.4% due to cardiovascular (CV) causes, mainly heart failure (HF, 34.6%). Non-CV deaths were attributed to sepsis (15.4%), malignancy (10.8%), trauma (3.8%), and multi-organ failure (1.5%). CV mortality accounted for 55% of deaths within 1 year and 68.4% beyond 5 years, with no significant change in the CV/non-CV mortality ratio over time. Among 88 survivors, non-fatal CV events were infrequent: 12.5% were rehospitalized for HF and 2.3% underwent repeat M-TEER. Non-CV hospitalizations occurred in 9.1%, mainly due to fractures or pneumonia. Independent predictors of all-cause mortality included ischemic secondary MR etiology, prior HF, TAPSE/sPAP ≤0.36, and ≥moderate tricuspid regurgitation, while a low MitraScore predicted better survival. A low MitraScore risk was associated with a significantly lower all-cause and CV mortality compared to a high Mitrascore risk (48.6% vs 83.9%, p < 0.001; 21.0% vs 64.4%, p ≤ 0.001). Long-term mortality after M-TEER remains influenced by extra-mitral cardiac involvement and non-cardiac comorbidities. The MitraScore preserves its prognostic accuracy during extended follow-up.
-
8. Reperfusion therapy for older patients with acute myocardial infarction and cardiogenic shock.
PMID:日期:2026-09-01Reperfusion therapy is the cornerstone of treatment for acute myocardial infarction (AMI) complicated by cardiogenic shock (CS). However, older adults with AMI and CS face higher risks of adverse outcomes and procedure-related complications. Since this population is under-represented in clinical trials, the efficacy of reperfusion therapy remains unclear. We performed a meta-analysis to evaluate the impact of reperfusion therapy on mortality in older adults with AMI and CS. We searched PUBMED and EMBASE through 4/1/2025 for studies comparing reperfusion therapy with percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) and non-reperfusion therapy for AMI and CS in patients aged ≥75 years. We included prospective and retrospective observational trials reporting clinical outcomes. The primary outcome was set as short-term mortality, and the secondary outcome was long-term mortality. We performed subgroup analysis of the primary outcome for patients with ST-segment elevation myocardial infarction and those without. Our search identified 14 eligible studies in a total of 4583 patients. Reperfusion therapy was associated with significantly reduced short-term mortality, compared with non-reperfusion therapy with high heterogeneity (odds ratio (OR): 0.47; 95% confidence interval (CI): 0.30-0.73, I = 76.8%). There was no significant difference in long-term all-cause mortality between reperfusion and non-reperfusion therapy (OR: 0.66; 95% CI: 0.34-1.26, I = 79.7%). The subgroup analyses were largely consistent with the main findings. Reperfusion therapy was associated with reduced short-term mortality, compared to non-reperfusion therapy for older patients with AMI and CS. Reperfusion therapy showed a tendency towards reduced long-term mortality.